Featured Publications
The Vascular Quality Initiative assessment of the Bard Lifestent for the treatment of popliteal artery occlusive disease
Bertges D, Eldrup-Jorgensen J, Eskandari M, Hamdan A, Mena-Hurtado C, Mewissen M, Smith T, Woo E, Cronenwett J, Initiative S. The Vascular Quality Initiative assessment of the Bard Lifestent for the treatment of popliteal artery occlusive disease. Journal Of Vascular Surgery 2023, 78: 1489-1496.e1. PMID: 37648091, DOI: 10.1016/j.jvs.2023.08.122.Peer-Reviewed Original ResearchConceptsTarget lesion revascularizationChronic limb-threatening ischemiaTarget vessel revascularizationMajor adverse eventsLimb-threatening ischemiaPopliteal arteryLesion revascularizationMajor amputationVessel revascularizationHemodynamic successSecondary patencyAdverse eventsOcclusive diseaseProcedural successSingle-arm prospective studyProximal popliteal arterySustained clinical successPrimary efficacy outcomePrimary safety outcomeArtery occlusive diseaseComposite primary endpointPrimary-assisted patencyKaplan-Meier analysisSuperficial femoral arteryMajority of stents
2020
Systematic review and meta-analysis of outcomes of lower extremity peripheral arterial interventions in patients with and without chronic kidney disease or end-stage renal disease
Anantha-Narayanan M, Sheikh AB, Nagpal S, Jelani QU, Smolderen KG, Regan C, Ionescu C, Ochoa Chaar CI, Schneider M, Llanos-Chea F, Mena-Hurtado C. Systematic review and meta-analysis of outcomes of lower extremity peripheral arterial interventions in patients with and without chronic kidney disease or end-stage renal disease. Journal Of Vascular Surgery 2020, 73: 331-340.e4. PMID: 32889074, DOI: 10.1016/j.jvs.2020.08.032.Peer-Reviewed Original ResearchConceptsCKD/end-stage renal diseaseEnd-stage renal diseaseNormal renal functionChronic kidney diseaseTarget lesion revascularizationLong-term mortalityPeripheral arterial diseaseRenal functionPAD interventionsMajor amputationRenal diseaseKidney diseaseOdds ratioNormal renal function groupIntervention typeRenal function groupCritical limb ischemiaPeripheral arterial interventionsConfidence intervalsPooled odds ratioOpen surgical approachMultivariable regression analysisCase-control matchingRandom-effects modelEvidence-based strategies
2017
Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease
Krishnan P, Faries P, Niazi K, Jain A, Sachar R, Bachinsky WB, Cardenas J, Werner M, Brodmann M, Mustapha JA, Mena-Hurtado C, Jaff MR, Holden AH, Lyden SP, Mewissen M, Katzen B, Nanjundappa A, Khuddus M, Ricci J, Fry D, Shishehbor M, Bosarge C, Kovach R, Goodwin M, Raja M, Mayeda G, Sandhu J, Rosales O, Crowder W, Paolini D, Henretta J, Desai P, Farhat N, Kang E, Ansel G, Ghani M, Miller W, Pollock C, Korngold E, Angle J, Schultz G, Gensler T, Lopez L, Park J, Al-Khoury G, Joels C, Metzger C. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease. Circulation 2017, 136: 1102-1113. PMID: 28729250, PMCID: PMC5598919, DOI: 10.1161/circulationaha.117.028893.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, BalloonCardiovascular AgentsCoated Materials, BiocompatibleFemaleFemoral ArteryHalf-LifeHumansKaplan-Meier EstimateMaleMiddle AgedPaclitaxelPeripheral Arterial DiseaseProspective StudiesSeverity of Illness IndexSingle-Blind MethodTime FactorsTreatment OutcomeVascular PatencyConceptsDrug-coated balloonsPrimary safety end pointSafety end pointTarget lesion revascularizationLesion revascularizationPrimary patencyEnd pointFemoropopliteal diseaseClinical outcomesPivotal studiesDifferent drug-coated balloonsPrimary effectiveness end pointStellarex drug-coated balloonTarget limb major amputationEffectiveness end pointAnkle-brachial indexProcedure-related deathsFemoropopliteal artery diseasePrimary patency rateDrug-Coated BalloonKaplan-Meier estimatesPaclitaxel plasma concentrationsQuality of lifeDCB cohortMajor amputationManagement of Isolated Atherosclerotic Stenosis of the Common Femoral Artery: A Review of the Literature
Halpin D, Erben Y, Jayasuriya S, Cua B, Jhamnani S, Mena-Hurtado C. Management of Isolated Atherosclerotic Stenosis of the Common Femoral Artery: A Review of the Literature. Vascular And Endovascular Surgery 2017, 51: 220-227. PMID: 28376704, DOI: 10.1177/1538574417702773.Peer-Reviewed Original ResearchConceptsCommon femoral endarterectomyTarget lesion revascularizationCommon femoral arteryCFA stenosisEndovascular therapyEndovascular studiesPrimary patencyAtherosclerotic stenosisTechnical successEndovascular interventionFemoral arteryGood short-term patencyFurther trial dataFirst-line therapyPercentage of patientsCritical limb ischemiaStandard of careNumber of patientsShort-term patencyLower ratesHigh rateEndovascular literatureFemoropopliteal systemLesion revascularizationLimb ischemia
2014
Randomized Controlled Study of Excimer Laser Atherectomy for Treatment of Femoropopliteal In-Stent Restenosis Initial Results From the EXCITE ISR Trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis)
Dippel EJ, Makam P, Kovach R, George JC, Patlola R, Metzger DC, Mena-Hurtado C, Beasley R, Soukas P, Colon-Hernandez PJ, Stark MA, Walker C, Investigators E. Randomized Controlled Study of Excimer Laser Atherectomy for Treatment of Femoropopliteal In-Stent Restenosis Initial Results From the EXCITE ISR Trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis). JACC Cardiovascular Interventions 2014, 8: 92-101. PMID: 25499305, DOI: 10.1016/j.jcin.2014.09.009.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlloysAmputation, SurgicalAngioplasty, BalloonAtherectomyChronic DiseaseCombined Modality TherapyConstriction, PathologicFemaleFemoral ArteryHumansLaser TherapyLasers, ExcimerLimb SalvageMaleMiddle AgedPeripheral Arterial DiseasePopliteal ArteryProspective StudiesProsthesis DesignRecurrenceStentsTime FactorsTreatment OutcomeUnited StatesVascular PatencyConceptsPercutaneous transluminal angioplastyTarget lesion revascularizationExcimer laser atherectomyLaser atherectomyAdjunctive percutaneous transluminal angioplastyMajor adverse event rateChronic peripheral artery diseaseLesion lengthLifestyle-limiting claudicationPrimary safety endpointRutherford class 1Target lesion lengthPrimary efficacy endpointMajor adverse eventsPeripheral artery diseaseAdverse event ratesCritical limb ischemiaFemoropopliteal ISRLesion revascularizationEfficacy endpointSafety endpointAdverse eventsLimb ischemiaTransluminal angioplastyArtery disease